| Literature DB >> 25874715 |
Shingo Noguchi1, Hiroshi Mukae1, Toshinori Kawanami1, Kei Yamasaki1, Kazumasa Fukuda2, Kentarou Akata1, Hiroshi Ishimoto1, Hatsumi Taniguchi2, Kazuhiro Yatera1.
Abstract
BACKGROUND: The causative pathogens of healthcare-associated pneumonia (HCAP) remain controversial, and the use of conventional cultivation of sputum samples is occasionally inappropriate due to the potential for oral bacterial contamination. It is also sometimes difficult to determine whether methicillin-resistant Staphylococcus aureus (MRSA) is a true causative pathogen of HCAP.Entities:
Mesh:
Substances:
Year: 2015 PMID: 25874715 PMCID: PMC4398420 DOI: 10.1371/journal.pone.0124697
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Patient inclusion and exclusion flow diagram.
Clinical and laboratory features of the 82 patients with HCAP.
| Age (y); mean ± SD | 75.5 ± 10.3 | Radiographic findings | |||||
| Sex (male / female) | 57 / 25 | Bilateral lung involvement | 42 | (51.2) | |||
| BMI; mean ± SD | 20.3 ± 4.0 | Pleural effusion | 24 | (29.3) | |||
| Comorbidity diseases | Previous antibiotic treatment | 13 | (15.9) | ||||
| Neoplastic disease | 25 | (30.5) | Use of antibiotics within the previous 90d | 28 | (34.1) | ||
| Chronic pulmonary disease | 37 | (45.1) | Smoking history | 34 | (41.5) | ||
| Cerebrovascular disease | 29 | (35.4) | Alcohol history | 19 | (23.2) | ||
| Chronic cardiac disease | 16 | (19.5) | Performance status | ||||
| Chronic liver disease | 7 | (8.5) | 0 | 10 | (12.2) | ||
| Chronic renal disease | 9 | (11.0) | 1 | 30 | (36.6) | ||
| Diabetes mellitus | 16 | (19.5) | 2 | 13 | (15.9) | ||
| Collagen disease | 9 | (11.0) | 3 | 11 | (13.4) | ||
| No comorbidity disease | 0 | (0.0) | 4 | 18 | (22.0) | ||
| Two or more comorbidities | 56 | (68.3) | |||||
| Mechanical ventilation | 13 | (15.9) | |||||
| Clinical parameters | |||||||
| Orientation disturbance (confusion) | 23 | (28.0) | Stratification by PSI | ||||
| Systolic BP < 90 mm Hg or diastolic | 20 | (24.4) | Ⅰ-Ⅲ | 15 | (18.3) | ||
| BP ≤ 60 mm Hg | ⅠV | 45 | (54.9) | ||||
| Pulse rate ≥ 125 beats/min | 9 | (11.0) | V | 22 | (26.8) | ||
| Respiratory rate ≥ 30 /min | 10 | (14.7) | |||||
| SpO2 ≤ 90%, PaO2 ≤ 60 mm Hg | 44 | (53.7) | In hospital mortality | 7 | (8.5) | ||
| Ⅰ-Ⅲ | 0 | (0.0) | |||||
| Laboratory findings | ⅠV | 3 | (3.7) | ||||
| pH < 7.35 | 7 | (13.7) | V | 4 | (4.9) | ||
| BUN ≥ 21mg/dl | 36 | (43.9) | |||||
| Na < 130 mEq/ml | 10 | (12.2) | |||||
| Glucose ≥ 250mg/dl | 2 | (2.4) | |||||
| Hematocrit < 30% | 16 | (19.5) | |||||
| Albumin < 3.0g/dl | 34 | (41.5) | |||||
Data are presented as n (%) or mean ± SD unless otherwise stated.
Definition of abbreviations: HCAP, healthcare-associated pneumonia; BMI, body mass index; BP, blood pressure; SpO2, pulse oximetric saturation; PaO2, partial pressure of arterial oxygen; BUN, blood urea nitrogen; PSI, pneumonia severity index; SD, standard deviation
§1BMI was evaluated in 59 patients
§2Respiratory rate was evaluated in 68 patients
§3Arterial blood gas analysis was performed in 51 patients
§4 0, can be active without any problems or limitations, daily life the same as before the onset; 1, intense activity limited, but can walk and perform light work or work while sitting; 2, can walk and perform all personal care, but cannot work; more than 50% of daytime hours out of bed; 3, can only do limited personal care; more than 50% of daytime hours spent in bed or chair; 4, cannot move at all or perform personal care, all day spent in bed or chair
Predominant bacteria according to the molecular method and conventional cultivation methods.
| Clone Library Method in BALF | Conventional Cultivation Methods | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Case detected as the predominant phylotype | All | BALF | Sputum | |||||||
| Gram-positive pathogens | ||||||||||
|
| 9 | (11.0) | 10 | (12.2) | 8 | (9.8) | 4 | (4.9) | ||
|
| 6 | (7.3) | 23 | (28.0) | 16 | (19.5) | 16 | (19.5) | ||
| Methicillin-susceptible | 11 | (13.4) | 6 | (7.3) | 7 | (8.5) | ||||
| Methicillin-resistant | 12 | (14.6) | 9 | (11.0) | 8 | (9.8) | ||||
|
| 1 | (1.2) | 1 | (1.2) | ||||||
|
| 19 | (23.2) | 10 | (12.2) | 9 | (11.0) | 6 | (7.3) | ||
|
| 4 | (4.9) | 1 | (1.2) | 1 | (1.2) | 1 | (1.2) | ||
|
| 15 | (18.3) | 9 | (11.0) | 8 | (9.8) | 5 | (6.1) | ||
|
| 4 | (4.9) | 5 | (6.1) | 4 | (4.9) | 1 | (1.2) | ||
|
| 1 | (1.2) | ||||||||
| Gram-negative pathogens | ||||||||||
|
| 14 | (17.1) | 9 | (11.0) | 8 | (9.8) | 3 | (3.7) | ||
|
| 1 | (1.2) | 2 | (2.4) | 2 | (2.4) | 1 | (1.2) | ||
|
| 3 | (3.7) | 10 | (12.2) | 7 | (8.5) | 6 | (7.3) | ||
|
| 8 | (9.8) | 16 | (19.5) | 14 | (17.1) | 8 | (9.8) | ||
|
| 1 | (1.2) | 1 | (1.2) | ||||||
|
| 2 | (2.4) | 3 | (3.7) | 2 | (2.4) | 1 | (1.2) | ||
|
| 1 | (1.2) | 2 | (2.4) | 1 | (1.2) | 1 | (1.2) | ||
|
| 2 | (2.4) | 2 | (2.4) | ||||||
|
| 1 | (1.2) | 1 | (1.2) | ||||||
|
| 1 | (1.2) | 1 | (1.2) | ||||||
|
| 2 | (2.4) | ||||||||
| Anaerobic pathogens | ||||||||||
|
| 3 | (3.7) | ||||||||
|
| 1 | (1.2) | ||||||||
|
| 2 | (2.4) | ||||||||
|
| 1 | (1.2) | ||||||||
|
| 1 | (1.2) | ||||||||
| Atypical pathogens | ||||||||||
|
| 1 | (1.2) | ||||||||
|
| 1 | (1.2) | 1 | (1.2) | 1 | (1.2) | 1 | (1.2) | ||
| Oral bacteria | 7 | (8.5) | 6 | (7.3) | 4 | (4.9) | ||||
| No pathogen identified | 2 | (2.4) | 13 | (15.9) | 23 | (28.0) | 39 | (47.6) | ||
| Total isolates | - | 105 | 83 | 53 | ||||||
Data are presented as n (%) unless otherwise stated. Percentage refer to the total number of patients (n = 82)
Definition of abbreviations: HCAP, healthcare-associated pneumonia; BALF, bronchoalveolar lavage fluid
§Including positive results of BALF and/or sputum culture, serological assessment, and urinary antigens
#The results of urinary antigen tests to detect Streptococcus pneumoniae were positive in 4 patients
Fig 2Comparison of the predominat phylotype and the rates of phylotypes of streptococci or anaerobes.
A) With respect to streptococci, the rate of a predominant phylotype was significantly higher in the patients equal to or older than 75 years of age (the rates of streptococci in the patients younger than 75 years old and equal to or older than 75 years of age were 12.1% and 31.9%, respectively; P<0.05); B) The rates of the phylotypes in each microbiota were significantly higher in the patients equal to or older than 75 years of age (<75 vs ≥75 were 11.0 ± 27.0% and 29.5 ± 34.1%, respectively; P<0.05); C-D) Regarding anaerobes, the rate of the predominant phylotype (<75 vs ≥75 were 11.8% vs 8.7%, respectively; P = 0.46) and the phylotypes in each microbiota (<75 vs ≥75 were 12.7 ± 26.5% vs 10.2 ± 23.1%, respectively; P = 0.66) were not significantly different between the two age groups.
The difference of bacteria according to the molecular method in sputum cultivation.
| Sputum | Clone Library Method in BALF | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| The number detected in cultivation | The predominant phylotype | The second phylotype | Less than the third phylotype (except others | Others | |||||||
| Gram-positive pathogens | |||||||||||
|
| 4 | 3 | (75.0) | 1 | (25.0) | ||||||
|
| 16 | 2 | (12.5) | 1 | (6.3) | 13 | (81.3) | ||||
|
| 1 | 1 | (100) | ||||||||
|
| 5 | 3 | (60.0) | 2 | (40.0) | ||||||
|
| |||||||||||
|
| 1 | 1 | (100) | ||||||||
| Gram-negative pathogens | |||||||||||
|
| 3 | 3 | (100.0) | ||||||||
|
| 1 | 1 | (100.0) | ||||||||
|
| 6 | 2 | (33.3) | 4 | (66.7) | ||||||
|
| 8 | 3 | (37.5) | 1 | (12.5) | 4 | (50.0) | ||||
|
| 1 | 1 | (100) | ||||||||
|
| 1 | 1 | (100) | ||||||||
|
| 1 | 1 | (100) | ||||||||
|
| 1 | 1 | (100.0) | ||||||||
Definition of abbreviations: BALF, bronchoalveolar lavage fluid
§The phylotypes that dominated less than 5% in each clone library were classified as "others"
Results of the molecular method and antibiotics efficacy in patients with positive cultivation of MRSA.
| No. | Cultivation | The results of Clone Library Method of 16S ribosomal RNA gene | Effective antibiotics | ||
|---|---|---|---|---|---|
| Sputum | BALF | BALF | |||
| Predominant phylotype (%, Clones/clones) | Proportion of | ||||
| 1 | MRSA, | MRSA, |
| MEPM→ TAZ/PIPC+VCM | |
|
|
| 43.0% (34/79) | 1.3% (1/79) | ||
| 2 | MRSA, | MSSA, |
| SBT/ABPC | |
|
|
| 100% (83/83) | 0% (0/83) | ||
| 3 | MRSA | MRSA |
| LVFX | |
| 81.6% (62/76) | 0% (0/76) | ||||
| 4 | MRSA | MRSA |
| TAZ/PIPC | |
| 73.6% (64/87) | 2.3% (2/87) | ||||
| 5 | MRSA | No growth |
| MEPM | |
| 55.0% (33/60) | 0% (0/60) | ||||
| 6 | MRSA, | MSSA |
| TAZ/PIPC | |
|
| 54.7% (52/95) | 54.7% (52/95) | |||
| 7 | MRSA, | MRSA, |
| LVFX | |
|
|
| 43.5% (40/92) | 12.0% (11/92) | →LZD | |
|
| |||||
| 8 | MRSA, | MRSA, |
| TAZ/PIPC | |
|
|
| 27.2% (25/92) | 0% (0/92) | ||
|
| |||||
| 9 | N.A | MRSA |
| MEPM+LZD | |
| 54.8% (46/84) | 23.8% (20/84) | ||||
| 10 | N.A | MRSA, |
| SBT/ABPC | |
|
| 70.7% (53/75) | 0% (0/75) | |||
|
| |||||
| 11 | N.A | MRSA, |
| TAZ/PIPC | |
|
| 97.4% (76/78) | 0% (0/78) | |||
| 12 | N.A | MRSA, |
| SBT/ABPC | |
|
| 58.9% (53/90) | 3.3% (3/90) | |||
Definition of abbreviation: MRSA, methicillin-resistant staphylococcus aureus; MSSA, methicillin-susceptible staphylococcus aureus; BALF, bronchoalveolar lavage fluid; SBT/ABPC, ampicillin/sulbactam; TAZ/PIPC, piperacillin/tazobactam; MEPM, meropenem; LVFX, levofloxacin; VCM, vancomycin; LZD, linezolid; N.A, not analyzed
§Case numbers were as follow: No.1, case35; No.2, case38; No.3, case39; No.4, case40; No.5, case44; No.6, case60; No.7, case66; No.8, case67; No.9, case31; No.10, case57; No.11, case63; No.12, case77